Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity

Abstract

Alpelisib represents an active treatment option in patients with recurrent gynecological cancers harboring a PIK3CA mutation. These findings support the need of biomarker-driven randomized trials of PI3K inhibitors in gynecological cancers.